Emerging biopharma startups are continuing their stronghold on the drug development pipeline. These potential therapies address a range of diseases, offering hope for innovative new treatments for patients. These companies face increased pressure to validate drug candidates earlier in the discovery and development lifecycle to ensure their viability. To prioritize and select the most viable drug candidates, startups must apply de-risking measures to determine the most probable regulatory pathway.